3.46
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAMP Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.62
Aprire:
$3.52
Volume 24 ore:
97,042
Relative Volume:
0.13
Capitalizzazione di mercato:
$70.26M
Reddito:
$264.74M
Utile/perdita netta:
$-49.71M
Rapporto P/E:
-0.8447
EPS:
-4.0959
Flusso di cassa netto:
$-43.55M
1 W Prestazione:
+5.93%
1M Prestazione:
+7.23%
6M Prestazione:
+95.79%
1 anno Prestazione:
-64.26%
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
Nome
Camp 4 Therapeutics Corp
Settore
Industria
Telefono
617-651-8867
Indirizzo
ONE KENDALL SQUARE, CAMBRIDGE, CA
Confronta CAMP con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
CAMP
Camp 4 Therapeutics Corp
|
3.485 | 74.80M | 264.74M | -49.71M | -43.55M | -4.0959 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
415.18 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
478.50 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
574.32 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
804.78 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
319.77 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-10-02 | Iniziato | Cantor Fitzgerald | Overweight |
2025-09-16 | Downgrade | JP Morgan | Overweight → Neutral |
2025-05-27 | Iniziato | Wedbush | Outperform |
2024-11-05 | Iniziato | JP Morgan | Overweight |
2024-11-05 | Iniziato | Piper Sandler | Overweight |
2024-11-05 | Iniziato | William Blair | Outperform |
2022-08-16 | Aggiornamento | Craig Hallum | Hold → Buy |
2021-12-22 | Downgrade | Craig Hallum | Buy → Hold |
2021-09-24 | Reiterato | Craig Hallum | Buy |
2021-06-25 | Reiterato | Craig Hallum | Buy |
2020-12-18 | Downgrade | JP Morgan | Neutral → Underweight |
2020-04-17 | Aggiornamento | Jefferies | Hold → Buy |
2020-03-05 | Reiterato | Craig Hallum | Buy |
2019-12-20 | Reiterato | Craig Hallum | Buy |
2019-12-20 | Downgrade | First Analysis Sec | Outperform → Neutral |
2019-06-28 | Aggiornamento | Northland Capital | Market Perform → Outperform |
2019-05-29 | Downgrade | Goldman | Neutral → Sell |
2019-05-01 | Reiterato | Craig Hallum | Buy |
2019-03-25 | Downgrade | JP Morgan | Overweight → Neutral |
2019-01-25 | Aggiornamento | JP Morgan | Neutral → Overweight |
2018-12-21 | Aggiornamento | Craig Hallum | Hold → Buy |
2018-12-14 | Reiterato | B. Riley FBR | Buy |
2018-12-11 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
2018-12-11 | Downgrade | Northland Capital | Outperform → Market Perform |
2018-11-27 | Iniziato | Goldman | Neutral |
2018-10-15 | Iniziato | Jefferies | Hold |
2018-09-28 | Reiterato | Craig Hallum | Hold |
2018-04-27 | Reiterato | Craig Hallum | Hold |
2018-03-08 | Downgrade | Craig Hallum | Buy → Hold |
2018-02-16 | Aggiornamento | First Analysis Sec | Equal-Weight → Overweight |
Mostra tutto
Camp 4 Therapeutics Corp Borsa (CAMP) Ultime notizie
How Camp4 Therapeutics Corporation stock reacts to global recession fears2025 Risk Factors & Safe Swing Trade Setup Alerts - newser.com
Risk adjusted return profile for Camp4 Therapeutics Corporation analyzedJuly 2025 Trade Ideas & Entry Point Confirmation Signals - newser.com
Is Camp4 Therapeutics Corporation a good long term investmentCup and Handle Formations & Low Entry Investment Portfolio - earlytimes.in
Combining price and volume data for Camp4 Therapeutics CorporationShort Setup & Technical Analysis for Trade Confirmation - newser.com
Can Camp4 Therapeutics Corporation stock reach $100 price targetPortfolio Performance Summary & Weekly Market Pulse Alerts - newser.com
Will Camp4 Therapeutics Corporation continue its uptrendPortfolio Return Report & AI Powered Market Entry Ideas - newser.com
CAMP4 Therapeutics stock soars after $100 million private placement By Investing.com - Investing.com Nigeria
CAMP4 Aims For The Summit: Unlocking The Therapeutic Power Of RegRNA, Once Deemed Undruggable - RTTNews
Camp4 Therapeutics Corporation Stock Analysis and ForecastSector Performance Review & Unlock Long-Term Capital Growth Ideas - earlytimes.in
Cantor Fitzgerald initiates CAMP4 Therapeutics stock with Overweight rating - Investing.com
CAMP4 Therapeutics begins toxicology studies for SYNGAP1 therapy By Investing.com - Investing.com Nigeria
Camp4 Therapeutics initiates GLP toxicology studies for CMP-SYNGAP-01 - MarketScreener
CAMP4 Initiates GLP Toxicology Studies for CMP-SYNGAP-01 - TipRanks
CAMP4 Therapeutics begins toxicology studies for SYNGAP1 therapy - Investing.com India
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01 - GlobeNewswire
Potential Breakthrough for Rare Brain Disorder: CAMP4's SYNGAP1 Drug Enters Final Pre-Clinical Stage - Stock Titan
What analysts say about Camp4 Therapeutics Corporation stockReal Estate Investment Trusts & These 3 Stocks Could Change Your Portfolio - Early Times
CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Price action breakdown for Camp4 Therapeutics CorporationWeekly Trend Summary & Technical Entry and Exit Alerts - newser.com
What’s next for Camp4 Therapeutics Corporation stock priceWeekly Trend Summary & Low Risk High Win Rate Stock Picks - newser.com
Is Camp4 Therapeutics Corporation reversing from oversold territoryJuly 2025 Big Picture & High Accuracy Trade Signal Alerts - newser.com
Applying chart zones and confluence areas to Camp4 Therapeutics CorporationMarket Growth Report & Free Long-Term Investment Growth Plans - newser.com
Backtesting results for Camp4 Therapeutics Corporation trading strategiesVolume Spike & Real-Time Volume Analysis Alerts - newser.com
How institutional ownership impacts Camp4 Therapeutics Corporation stockChart Signals & Safe Entry Momentum Tips - newser.com
Building trade automation scripts for Camp4 Therapeutics CorporationOptions Play & Consistent Profit Focused Trading Strategies - newser.com
Aug Spikes: Whats the beta of LILAK stockJuly 2025 Movers & Verified Momentum Stock Ideas - khodrobank.com
Trend analysis for Camp4 Therapeutics Corporation this weekCPI Data & High Return Stock Watch Alerts - newser.com
Analyzing Camp4 Therapeutics Corporation with multi timeframe chartsWeekly Trade Recap & Breakout Confirmation Alerts - newser.com
Aug Movers: Will Camp4 Therapeutics Corporation outperform the market in YEAR2025 Trading Recap & Real-Time Stock Entry Alerts - خودرو بانک
Patterns Watch: What are Camp4 Therapeutics Corporation’s recent SEC filings showingOptions Play & High Accuracy Swing Entry Alerts - khodrobank.com
Using AI based signals to follow Camp4 Therapeutics CorporationM&A Rumor & AI Optimized Trade Strategies - newser.com
Earnings Recap: Can ProShares Trust ProShares UltraShort SmallCap600 beat the S&P 500Quarterly Market Summary & Weekly High Return Stock Forecasts - خودرو بانک
Support Test: Is Camp4 Therapeutics Corporation likely to announce a buybackJuly 2025 Gainers & Weekly Consistent Profit Watchlists - خودرو بانک
Can volume confirm reversal in Camp4 Therapeutics CorporationJuly 2025 Short Interest & Stepwise Entry/Exit Trade Alerts - newser.com
Camp 4 Therapeutics Corp Azioni (CAMP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Camp 4 Therapeutics Corp Azioni (CAMP) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Polaris Management Co. VII, L. | 10% Owner |
Sep 11 '25 |
Buy |
1.53 |
1,307,189 |
1,999,999 |
2,825,500 |
Nashat Amir | Director |
Sep 11 '25 |
Buy |
1.53 |
1,307,189 |
1,999,999 |
2,825,500 |
Maricich Yuri | Chief Medical Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
6,060 |
Gold Kelly | Chief Financial Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
67,877 |
Mandel-Brehm Josh | Chief Executive Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
278,417 |
Young Richard A | Director |
Sep 11 '25 |
Buy |
1.65 |
15,151 |
24,999 |
170,010 |
Northpond Ventures II GP, LLC | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
763,636 |
8,399,996 |
763,636 |
AH Equity Partners Bio I, L.L. | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
727,272 |
7,999,992 |
1,579,885 |
Enavate Sciences GP, LLC | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
1,363,636 |
14,999,996 |
3,785,802 |
Polaris Management Co. VII, L. | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
909,090 |
9,999,990 |
909,090 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):